- Home
- LVLU vs FBIO Comparison
LVLU vs FBIO Comparison
Compare LVLU & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | FBIO |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 113.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVLU | FBIO |
|---|---|---|
| Price | $5.44 | $3.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $15.00 | ★ $16.50 |
| AVG Volume (30 Days) | 21.8K | ★ 531.9K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,413,000.00 | $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | $2.53 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.98 | $1.33 |
| 52 Week High | $18.00 | $4.20 |
Technical Indicators
Market Signals| Indicator | LVLU | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 74.11 |
| Support Level | $5.22 | $3.31 |
| Resistance Level | $5.83 | $3.75 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 35.76 | 93.69 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.